The Effectiveness of Novel e-Health Applications for the Management of Obesity in Childhood and Adolescence During the COVID-19 Outbreak in Greece.

Publication date: Jun 27, 2025

Background/Objectives: The prevalence of childhood obesity has recently increased, particularly during the COVID-19 pandemic, owing to lifestyle changes as a result of public health regulations and guidelines introduced by governments worldwide. The aim of our study was to evaluate the impact of novel e-Health applications in addressing childhood obesity prior to and during the COVID-19 pandemic. Methods: The study was conducted as part of the four-year European project BigO (Horizon2020, No. 727688). A total of 86 children and adolescents with overweight and obesity (mean age +/- standard error of the mean: 11. 82 +/- 0. 25 years; 49 males, 37 females; 31 prepubertal, 55 pubertal) were studied prospectively for 1 year prior to the pandemic (non-COVID-19 group, n = 50) and during the pandemic (COVID-19 group, n = 36). Based on the body mass index (BMI), subjects were classified as having morbid obesity (n = 40, 46,51%) obesity (n = 21, 24. 42%), overweight (n = 22, 25. 58%), and normal ΒΜΙ (n = 3, 3. 49%) according to the International Obesity Task Force cut-off points. The data collection system utilized the BigO technology platform, which connects to a smartphone and smartwatch to objectively record each patient’s diet, sleep, and physical activity. Participants used the BigO system continuously for 4 weeks and wore the smartwatch for specific periods during the week. Subsequently, they entered a personalized, multidisciplinary lifestyle intervention program for 4 months and used the system again for 4 weeks. Results: The key finding was a significantly higher improvement rate in BMI category among children and adolescents during the COVID-19 pandemic (58. 3%) compared to before the pandemic (36%). Both groups showed significant reductions in BMI, BMI z-score, insulin resistance indices (homeostatic model assessment and quantitative insulin sensitivity check index), blood pressure, gamma-glutamyl transferase, and insulin concentrations, alongside increases in high-density lipoprotein cholesterol (p < 0. 01). Notably, the COVID-19 group experienced a significantly greater reduction in BMI z-score at 12 months compared to the non-COVID-19 group (p < 0. 05). Conclusions: Our results reveal that the COVID-19 group demonstrated better compliance with lifestyle interventions and experienced more significant improvements in cardiometabolic risk factors. This suggests that the innovative e-Health applications were successful in managing childhood obesity despite the challenges caused by the COVID-19 pandemic.

Open Access PDF

Concepts Keywords
Females Adolescent
Greece Body Mass Index
Homeostatic Child
Horizon2020 childhood obesity
Obesity COVID-19
COVID-19 pandemic
digital health tools
e-Health intervention
Female
Greece
Humans
Male
Mobile Applications
Pandemics
Pediatric Obesity
Prospective Studies
SARS-CoV-2
Telemedicine

Semantics

Type Source Name
disease MESH Obesity in Childhood
disease MESH COVID-19
disease MESH lifestyle
disease MESH overweight
disease MESH obesity
disease MESH morbid obesity
disease IDO intervention
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease IDO blood
drug DRUGBANK Cholesterol
drug DRUGBANK Tropicamide
pathway REACTOME Metabolism
drug DRUGBANK Coenzyme M
disease MESH Sedentary lifestyle
disease MESH complications
disease MESH morbidity
disease IDO country
disease MESH psychological stress
disease MESH weight gain
drug DRUGBANK Spinosad
disease MESH emergencies
disease IDO history
disease MESH inadequate sleep
drug DRUGBANK Tretamine
drug DRUGBANK Methionine
disease MESH sleep quality
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Lysergic acid diethylamide
disease MESH fatty liver
disease MESH hypertension
disease MESH metabolic syndrome
disease MESH chronic diseases
drug DRUGBANK Trestolone
disease MESH privacy
drug DRUGBANK Etoperidone
disease MESH causes
disease MESH loneliness
disease MESH diabetes mellitus
disease MESH cardiovascular risk

Original Article

(Visited 2 times, 1 visits today)